Letters, Statements & Analysis (2020)

Communicating the importance of managed care pharmacy is a key part of AMCP’s work. Using AMCP policies as a basis for their work, AMCP staff and volunteers provide comments, analysis and testimony to Congress and other federal and state agencies on how proposed regulations and laws impact managed care pharmacy and the patients we serve.

March

3/9/2020

AMCP joins stakeholder letter on FDA proposed drug importation rule

3/6/2020

AMCP submits comments on the Advanced Notice of Methodological Changes for Calendar Year (CY) 2021 for Medicare Advantage (MA) Capitation Rates and Part C and Part D

3/2/2020

AMCP submits comments on the CY 2021 Affordable Care Act Notice of Benefit and Payment Parameters

February

2/21/2020

AMCP submits comments on FDA draft guidance on the drug manufacturer importation pathway

2/5/2020

Summary: Medicare and Medicaid Programs; Contract Year 2021 and 2022 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicaid Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly

Summary: Advance Notice of Methodological Changes for Calendar Year (CY) 2021 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies – Part II

January

1/1/2020

AMCP Submits Comments to HHS OIG on Proposed Changes to the Federal Anti-Kickback Statute